Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Director departure
Appointed director
Aceragen, Inc. (IDRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/14/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results"
05/05/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/09/2021 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
10/29/2020 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances"
08/04/2020 8-K Quarterly results
05/01/2020 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Financial Resources Through Critical Catalyst of Phase 3 ORR Readout and Potentially Beyond",
"Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders 2020 Annual Meeting of Stockholders will be held in a virtual format"
11/06/2019 8-K Quarterly results
Docs: "Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results EXTON, PA, November 6, 2019 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today reported its operational and financial results for the third quarter ended September 30, 2019. “The third quarter of this year marked another consecutive period of focused execution for our company as we continue advancing tilsotolimod for patients and their families,” stated Vincent Milano, Idera's Chief Executive Officer. “During this quarter, we implemented adjustments for ILLUMINATE-301 and continue to make meaningful progress with patient e..."
08/08/2019 8-K Quarterly results
Docs: "Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results EXTON, PA, August 8, 2019 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today reported its operational and financial results for the second quarter ended June 30, 2019. “Our team has demonstrated remarkable focus on execution during the first half of this year. We have made significant progress developing tilsotolimod and advancing it forward for patients facing the challenges of late-stage, anti-PD-1 refractory metastatic melanoma,” stated Vincent Milano, Idera's Chief Executive Officer. “Our accrual rate in the registrat..."
05/02/2019 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update EXTON, PA, May 2, 2019 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today reported its financial and operational results for the first quarter ended March 31, 2019. “The first quarter of this year represented another period of solid execution from everyone on our team,” stated Vincent Milano, Idera's Chief Executive Officer. “During this quarter, we completed enrollment of ILLUMINATE-204, positioning ourselves to provide a full analysis from this trial in the fourth quarter of this year. We've also made significant progres..."
03/06/2019 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update - ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 - - ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 - - ILLUMINATE-206 Trial Expected to Initiate Q2 2019 - - Chief Medical Officer Dr. Joanna Horobin Announces Retirement Plan - - Company to Present at Barclays Global Healthcare Conference Next Week - EXTON, PA, March 6, 2019 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs, today reported its financial..."
11/06/2018 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update — Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 — — Cash runway into first quarter of 2020 — EXTON, PA, November 6, 2018 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs, today reported its financial and operational results for the third quarter ended September 30, 2018. “The third quarter of 2018 was marked by continued focus and execution throughout our company advancing the tilsotolimod ILLUMINATE 301 ..."
10/28/2016 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results CAMBRIDGE, MA and EXTON, PA. October 28, 2016 — Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the third quarter ended September 30, 2016. Since June 30, 2016, the Company:"
11/05/2009 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update"
03/04/2008 8-K Quarterly results, Appointed a new director
Docs: "- PRESS RELEASE ISSUED BY IDERA PHARMACEUTICALS, INC. ON MARCH 4, 2008."
03/31/2005 8-K Quarterly results
Docs: "RELEASE ISSUED BY HYBRIDON, INC."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy